NCT04998812ocrelizumabMS
…MINORE ( NCT04998812) is a prospective Phase IV, open-label study measuring ocrelizu…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04998812 ×
NCT04998812
This funder is selected. Its supporting articles are shown below.